Aridis Pharmaceuticals Inc (NASDAQ:ARDS)’s share price reached a new 52-week low on Thursday . The stock traded as low as $7.59 and last traded at $8.54, with a volume of 10634 shares trading hands. The stock had previously closed at $8.50.

ARDS has been the subject of several research analyst reports. Zacks Investment Research raised shares of Aridis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a research note on Tuesday, November 13th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $25.00 target price on shares of Aridis Pharmaceuticals in a research note on Tuesday, November 13th. Maxim Group set a $25.00 target price on shares of Aridis Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, November 13th. Laidlaw initiated coverage on shares of Aridis Pharmaceuticals in a research note on Monday, September 10th. They set a “buy” rating and a $23.00 target price for the company. Finally, Northcoast Research initiated coverage on shares of Aridis Pharmaceuticals in a research note on Monday, September 10th. They set an “outperform” rating and a $40.00 target price for the company. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Aridis Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $25.40.

Aridis Pharmaceuticals (NASDAQ:ARDS) last posted its earnings results on Tuesday, November 13th. The company reported ($1.97) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.05) by ($0.92). The company had revenue of $1.02 million for the quarter, compared to the consensus estimate of $0.33 million. On average, equities research analysts expect that Aridis Pharmaceuticals Inc will post -3.05 earnings per share for the current year.

WARNING: This story was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another website, it was copied illegally and reposted in violation of US and international copyright & trademark legislation. The original version of this story can be accessed at https://www.thecerbatgem.com/2018/12/06/aridis-pharmaceuticals-ards-hits-new-52-week-low-at-7-59.html.

About Aridis Pharmaceuticals (NASDAQ:ARDS)

Aridis Pharmaceuticals, Inc engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-105, AR-101, AR-401, AR-201, and AR-501. The company was founded by Eric J. Patzer and Vu L.

See Also: Retained Earnings

Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.